In a move to curb monopolistic practices in the pharmaceutical industry, China’s State Council Antimonopoly and Anti-Unfair Competition Commission has introduced (26 January) the “Guidelines for Antitrust in the Pharmaceutical Sector”. The Guidelines aim to ensure fair competition, protect consumer interests, and safeguard public welfare in the pharmaceutical market, in line with the Anti-Monopoly Law of the People’s Republic of China.
Background and Need
The pharmaceutical industry, a vital component of China’s economy, is directly linked to public health and well-being. However, monopolistic behaviors such as price manipulation and supply chain control have hindered market fairness, leading to widespread public concern. In 2021, the State Council issued antitrust guidelines targeting active pharmaceutical ingredients (APIs), successfully regulating monopolistic practices in that niche. Yet, the growing complexity of antitrust issues in the broader pharmaceutical sector has necessitated a comprehensive framework. The new Guidelines expand on previous efforts, covering the entire pharmaceutical value chain and providing tailored solutions to address unique industry challenges.
Development Process
The formulation of the Guidelines was a multi-step, collaborative effort:
- Research on Key Issues: Authorities conducted in-depth studies on common monopolistic behaviors and regulatory gaps in the pharmaceutical sector.
- Industry Consultation: Engaging with stakeholders, including government bodies, pharmaceutical companies, and academic experts, to ensure practical and enforceable provisions.
- Public Feedback: In August 2024, the draft was opened for public consultation via the State Administration for Market Regulation’s (SAMR) website.
- Expert Validation: Legal, economic, and industry professionals reviewed and refined the Guidelines, fostering a broad consensus.
Key Provisions
The Guidelines comprise 7 chapters and 55 articles, offering detailed principles and rules for addressing antitrust issues specific to the pharmaceutical sector:
- General Principles: Establishes a framework for fair competition, emphasizing market self-regulation and robust compliance systems.
- Monopoly Agreements: Details behaviors such as horizontal collusion, vertical restraints, and reverse payment agreements, alongside conditions for exemption.
- Abuse of Market Dominance: Identifies practices like excessive pricing, supply restrictions, and product-hopping, with clear criteria for enforcement.
- Merger Control: Introduces criteria for analyzing the competitive impact of mergers, even those below reporting thresholds, particularly in transactions involving intellectual property.
- Fair Competition Review: Specifies requirements for assessing government policies that may restrict competition, focusing on barriers to market entry and procurement.
- Legal Consequences: Outlines penalties for violations, including provisions for leniency, exemptions, and enhanced penalties for non-cooperation.
Distinctive Features
- Comprehensive Scope: Extends to all pharmaceutical categories, including traditional Chinese medicine, chemical drugs, and biologics, covering the entire supply chain.
- Problem-Oriented Approach: Draws on past enforcement experiences, addressing emerging issues like online sales and patent abuse.
- Balanced Enforcement: Combines stringent penalties with clear exemptions to foster innovation while deterring misconduct.
- Collaborative Governance: Encourages industry associations and companies to enhance compliance, supported by interagency cooperation for efficient enforcement.
Significance
The Guidelines represent a critical step in China’s effort to build a fair, transparent, and innovation-friendly pharmaceutical market. By setting clear rules and fostering collaborative oversight, they aim to prevent monopolistic practices while encouraging healthy competition and industry growth.
The implementation of these Guidelines is expected to not only bolster public confidence in drug pricing and availability but also serve as a model for antitrust regulation in other sectors.
Source: https://www.samr.gov.cn/xw/mtjj/art/2025/art_39891b1c2067409bba29e17cee41d869.html
